BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Atritech, Inc. Announces FDA Regulatory Update


3/19/2010 11:12:24 AM

MINNEAPOLIS, March 18 /PRNewswire/ -- Atritech, Inc., an emerging medical device company, announced today that it has obtained clarity from the U.S. Food and Drug Agency (FDA) on the regulatory path towards full approval of its WATCHMAN® Left Atrial Appendage (LAA) Closure Technology in the United States.

In a recent letter received from the FDA, the agency requested that a confirmatory study be conducted to further substantiate the safety and effectiveness of the WATCHMAN® LAA Closure Technology in patients with atrial fibrillation at risk of stroke and eligible for anticoagulation therapy. Atritech will be working closely with the FDA to finalize the study design and is looking to start the confirmatory study later this year.

Earlier this week, American College of Cardiology's (ACC) President-Elect Dr. David Holmes, presented 1350 patient years of follow up data from the PROTECT AF clinical trial at the annual ACC meeting in Atlanta. Highlights of the data include a 31% risk reduction in all stroke, cardiovascular death and systemic thromboembolism in the WATCHMAN group as compared to patients on Warfarin. The results presented were comparable to those presented in the initial data published in the Lancet, August 2009.

The PROTECT AF clinical trial evaluated the WATCHMAN® LAA Closure Device versus the current standard of care, Warfarin, in patients with non-valvular atrial fibrillation. February 2010 marked the 5-year anniversary of the first enrollment in the PROTECT AF trial. The trial enrolled a total of 800 patients and now has an average follow up of two years. PROTECT AF is the only prospective, randomized clinical trial comparing an LAA closure device to long term Warfarin therapy. In August 2008, the company began enrolling patients in a Continued Access Study in the U.S. and now has over 420 patients implanted.

"The adoption of the WATCHMAN technology in markets outside of the US has been largely due to the compelling data contained in the PROTECT AF clinical trial. The initiation of a confirmatory study combined with the continued follow up of our study patients will further establish the clinical significance of this important technology," said Jim Bullock, President and CEO of Atritech.

About Atritech

Atritech is a privately held company based in Plymouth, Minnesota. Major investors in Atritech include Split Rock Partners, Thomas, McNerney and Partners, Prism Venture Partners, Tullis Health Investment Funds, The Vector Group, Thoma Cressey Funds, The Rahn Group, SightLine Partners and Affinity Capital. For more information, visit www.atritech.net.

SOURCE Atritech, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES